| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer
1 company
Stephen S. Dominy last filed a Form 4 in January 2022, as Chief Scientific Officer at QNCX. Stephen S. Dominy's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 1,217,086 shares of QNCX. Net of sales, the QNCX filings show accumulation of 763 shares.
Stephen S. Dominy has 4 Form 4 filings on record from February 2020 to January 2022, all as Chief Scientific Officer at Quince Therapeutics (QNCX), 2020–2022.
The 5 reported transactions were 4 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $11K and no sales.
The only open-market purchase was 763 shares of QNCX at an average $14.40 on November 12, 2021, about $11K. Twelve months later QNCX was down 94%.
Shares as reported in the last Form 4 for each company; the most recent is from January 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2021 | QNCX Quince Therapeutics, Inc. | Chief Scientific Officer | Buy | 763 | $14.40 | $10,987.20 | - | -61.6% | -94.2% |